Compare · CGC vs DFTX
CGC vs DFTX
Side-by-side comparison of Canopy Growth Corporation (CGC) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $3.88B, about 21.1x CGC ($183.7M).
- Over the past year, CGC is down 62.3% and DFTX is up 141.1% - DFTX leads by 203.4 points.
- DFTX has been more active in the news (9 items in the past 4 weeks vs 3 for CGC).
- CGC has more recent analyst coverage (19 ratings vs 8 for DFTX).
- Company
- Canopy Growth Corporation
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $183.7M
- $3.88B
- 1M return
- -35.03%
- -21.27%
- 1Y return
- -62.27%
- +141.13%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 9
- Recent ratings
- 19
- 8
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Latest CGC
- Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets Cannabis
- SEC Form 10-Q filed by Canopy Growth Corporation
- Canopy Growth Announces Results of 2026 Annual General and Special Meeting of Shareholders
- SEC Form 8-K filed by Canopy Growth Corporation
- Canopy Growth to Report Second Quarter Fiscal 2027 Financial Results on November 6, 2026
- SEC Form DEFA14A filed by Canopy Growth Corporation
- SEC Form 8-K filed by Canopy Growth Corporation
- Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower
- SEC Form DEFA14A filed by Canopy Growth Corporation
Latest DFTX
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026